MedImmune Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PENNY who wrote (13)	3/29/1997 2:45:00 PM
From: Dr. Bob	of 416

A couple points of clarification: 1. In a blinded trial, no-one knows the results until they're published, except the scientists actually analyzing the data - not the ones at the site using the drug. Anyone who says they're "really excited about the results" could only be referring to evidence that the drug is safe, not efficacious. 2. There is a shortage of RespiGam, which is good for the company and will certainly support prices at their current levels, but do not expect a big price increase next year - the price already is a factor in some physicians choosing not to use the drug. MedImmune will make more money by keeping the price where it is and selling more drug than by raising the price considerably, and thereby discouraging these non-users and maybe even some of the current users from using it at all, and I think they recognize that. I like this company and this stock; I do not own it because of a conflict of interest as a user of their primary product, but good luck to all of you who do! Bob

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next